Association of psoriasis severity with health-related quality of life, depression, and work productivity - 09/05/15
April Armstrong, MD, MPH, Department of Dermatology, University of Colorado Denver, Aurora, CO, United States; Andrew Robertson, PhD, National Psoriasis Foundation, Portland, OR, United States; Emily Edson-Heredia, MPH, Eli Lilly and Company, Indianapolis, IN, United States; Baojin Zhu, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Enkeleida Nikai, Eli Lilly S.A., Bruxelles, Belgium; Alison Potts Bleakman, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Mark Lebwohl, MD, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Le texte complet de cet article est disponible en PDF.| 100% sponsored by Eli Lilly and Company. |
Vol 72 - N° 5S1
P. AB226 - mai 2015 Retour au numéro
Article précédent
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week results from the ESTEEM 2 study
- Cardiovascular risk factors in patients with moderate to severe psoriasis: Integrated prevalence and safety data from 5 randomized controlled trials of adalimumab
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?